Robotic stereotactic radiotherapy for liver oligometastases from colorectal cancer: a single-center experience.
Colorectal cancer
Liver metastases
Oligometastases
Stereotactic body radiotherapy
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
01
10
2018
accepted:
08
05
2019
pubmed:
20
5
2019
medline:
11
10
2019
entrez:
20
5
2019
Statut:
ppublish
Résumé
To report on the safety and clinical benefit of robotic stereotactic radiotherapy (SBRT) for liver oligometastatic colorectal cancer (CRC). Robotic SBRT was applied to oligometastatic CRC patients, defined as having 1-4 liver metastases and absent or controlled extrahepatic disease. The intended prescription dose was 37.5 Gy in three fractions. Treatment efficacy was estimated by clinical benefit rate (CBR), progression-free survival (PFS) and overall survival (OS). Toxicity was graded according to CTC-AE scale, v. 4.03. Regression analysis was performed to search for the presence of any predictive factors. Between 2012 and 2017, 38 patients (66 lesions) were irradiated. The median delivered biological effective maximum dose (maxBED Our analysis underlines the importance of patients' selection to identify the oligometastatic scenario most likely to benefit from SBRT. Prospective studies are needed to further assess its role among locoregional treatment options for liver metastases from CRC.
Identifiants
pubmed: 31104277
doi: 10.1007/s11547-019-01042-8
pii: 10.1007/s11547-019-01042-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
870-876Références
Int J Cancer. 2002 Oct 10;101(5):403-8
pubmed: 12216066
Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7
pubmed: 15166961
Front Radiat Ther Oncol. 2004;38:100-5
pubmed: 15458194
J Surg Oncol. 2004 Dec 15;88(4):261-6
pubmed: 15565587
Acta Oncol. 2006;45(7):823-30
pubmed: 16982546
J Clin Oncol. 2007 Mar 10;25(8):947-52
pubmed: 17350943
Arch Surg. 2008 Dec;143(12):1204-12
pubmed: 19075173
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2009 Apr 1;27(10):1572-8
pubmed: 19255321
CA Cancer J Clin. 2009 May-Jun;59(3):145-70
pubmed: 19364702
J Clin Oncol. 2009 Aug 1;27(22):3677-83
pubmed: 19470929
Cardiovasc Intervent Radiol. 2010 Feb;33(1):11-7
pubmed: 19924474
Cancer J. 2010 Mar-Apr;16(2):150-5
pubmed: 20404612
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Nat Rev Clin Oncol. 2011 Jun;8(6):378-82
pubmed: 21423255
Cancer. 2011 Sep 1;117(17):4060-9
pubmed: 21432842
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1047-57
pubmed: 22284028
Dan Med J. 2012 Jun;59(6):A4444
pubmed: 22677242
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):336-42
pubmed: 23433800
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Onco Targets Ther. 2014 Jun 12;7:915-23
pubmed: 24959080
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Asian Pac J Cancer Prev. 2016;17(5):2545-8
pubmed: 27268627
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1399-1404
pubmed: 27319288
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Oncol Lett. 2017 Mar;13(3):1087-1094
pubmed: 28454218
Clin Colorectal Cancer. 2017 Dec;16(4):349-357.e1
pubmed: 28462852
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047